Literature DB >> 12788248

Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD).

Gary S Sachs1, Michael E Thase, Michael W Otto, Mark Bauer, David Miklowitz, Stephen R Wisniewski, Philip Lavori, Barry Lebowitz, Mathew Rudorfer, Ellen Frank, Andrew A Nierenberg, Maurizio Fava, Charles Bowden, Terence Ketter, Lauren Marangell, Joseph Calabrese, David Kupfer, Jerrold F Rosenbaum.   

Abstract

The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) was conceived in response to a National Institute of Mental Health initiative seeking a public health intervention model that could generate externally valid answers to treatment effectiveness questions related to bipolar disorder. STEP-BD, like all effectiveness research, faces many design challenges, including how to do the following: recruit a representative sample of patients for studies of readily available treatments; implement a common intervention strategy across diverse settings; determine outcomes for patients in multiple phases of illness; make provisions for testing as yet undetermined new treatments; integrate adjunctive psychosocial interventions; and avoid biases due to subject drop-out and last-observation-carried-forward data analyses. To meet these challenges, STEP-BD uses a hybrid design to collect longitudinal data as patients make transitions between naturalistic studies and randomized clinical trials. Bipolar patients of every subtype with age >/= 15 years are accessioned into a study registry. All patients receive a systematic assessment battery at entry and are treated by a psychiatrist (trained to deliver care and measure outcomes in patients with bipolar disorder) using a series of model practice procedures consistent with expert recommendations. At every follow-up visit, the treating psychiatrist completes a standardized assessment and assigns an operationalized clinical status based on DSM-IV criteria. Patients have independent evaluations at regular intervals throughout the study and remain under the care of the same treating psychiatrist while making transitions between randomized care studies and the standard care treatment pathways. This article reviews the methodology used for the selection and certification of the clinical treatment centers, training study personnel, the general approach to clinical management, and the sequential treatment strategies offered in the STEP-BD standard and randomized care pathways for bipolar depression and relapse prevention.

Entities:  

Mesh:

Year:  2003        PMID: 12788248     DOI: 10.1016/s0006-3223(03)00165-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  159 in total

1.  Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuse.

Authors:  Diane Warden; Madhukar H Trivedi; Tracy L Greer; Edward Nunes; Bruce D Grannemann; Viviana E Horigian; Eugene Somoza; Kolette Ring; Tiffany Kyle; José Szapocznik
Journal:  Contemp Clin Trials       Date:  2011-09-17       Impact factor: 2.226

2.  What have we learned about trial design from NIMH-funded pragmatic trials?

Authors:  John March; Helena C Kraemer; Madhukar Trivedi; John Csernansky; John Davis; Terence A Ketter; Ira D Glick
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

3.  Enhancing medication adherence: in older adults with bipolar disorder.

Authors:  Colin A Depp; Barry D Lebowitz
Journal:  Psychiatry (Edgmont)       Date:  2007-06

4.  Testing for clinical inertia in medication treatment of bipolar disorder.

Authors:  Dominic Hodgkin; Elizabeth L Merrick; Peggy L O'Brien; Thomas G McGuire; Sue Lee; Thilo Deckersbach; Andrew A Nierenberg
Journal:  J Affect Disord       Date:  2016-06-21       Impact factor: 4.839

Review 5.  Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.

Authors:  Eleanor Murphy; Francis J McMahon
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

6.  Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.

Authors:  Joel Jakobsson; Maria Bjerke; Sara Sahebi; Anniella Isgren; Carl Johan Ekman; Carl Sellgren; Bob Olsson; Henrik Zetterberg; Kaj Blennow; Erik Pålsson; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2015-07       Impact factor: 6.186

7.  An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial.

Authors:  Ellen Frank; Meredith L Wallace; Martica Hall; Brant Hasler; Jessica C Levenson; Carol A Janney; Isabella Soreca; Matthew C Fleming; Joan Buttenfield; Fiona C Ritchey; David J Kupfer
Journal:  Bipolar Disord       Date:  2014-12-12       Impact factor: 6.744

8.  Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).

Authors:  Michael J Ostacher; Roy H Perlis; Andrew A Nierenberg; Joseph Calabrese; Jonathan P Stange; Ihsan Salloum; Roger D Weiss; Gary S Sachs
Journal:  Am J Psychiatry       Date:  2009-12-15       Impact factor: 18.112

9.  Do Sleep Disturbances Predict or Moderate the Response to Psychotherapy in Bipolar Disorder?

Authors:  Louisa G Sylvia; Stephanie Salcedo; Amy T Peters; Pedro Vieira da Silva Magalhães; Ellen Frank; David J Miklowitz; Michael W Otto; Michael Berk; Andrew A Nierenberg; Thilo Deckersbach
Journal:  J Nerv Ment Dis       Date:  2017-03       Impact factor: 2.254

10.  Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study.

Authors:  Rodrigo Machado-Vieira; David A Luckenbaugh; Elizabeth D Ballard; Ioline D Henter; Mauricio Tohen; Trisha Suppes; Carlos A Zarate
Journal:  Am J Psychiatry       Date:  2016-08-13       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.